Physician profile
Michelle Nye
NPI 1578113072
$7,766.85
in general payments reported to CMS, 2019-2025
23 companies · $2,972 in 2025
The $2,972 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $221 · 2023: $1,913 · 2024: $2,416 · 2025: $2,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,695 · Education: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,694.83 |
| Education | $606.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,163.54 | 2023-2025 | |
| Janssen Biotech, INC. | $925.23 | 2023-2025 | Tremfya |
| Incyte Corporation | $719.59 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $596.47 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $582.50 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $577.99 | 2022-2025 | Dupixent |
| Amgen INC. | $417.11 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $329.45 | 2023-2025 | Zoryve |
| Ucb, INC. | $328.28 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $322.06 | 2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $303.28 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $275.65 | 2022-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.67 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Novartis Pharmaceuticals Corporation | $220.78 | 2023-2025 | |
| Genzyme Corporation | $202.40 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $116.54 | 2024 | Tremfya |
| Organogenesis INC. | $102.20 | 2024-2025 | Puraply Wound Matrix |
| Lilly USA, LLC | $94.90 | 2024-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $85.29 | 2023-2024 | Vtama |
| Almirall LLC | $72.21 | 2024-2025 | Klisyri |
| Organon LLC | $54.43 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.11 | 2025 | Spevigo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Nye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.